Ubiquitin proteasome system (UPS) activation in the cardiac hypertrophy of hyperthyroidism

[1]  Hui-Hua Li,et al.  Resveratrol as a new inhibitor of immunoproteasome prevents PTEN degradation and attenuates cardiac hypertrophy after pressure overload , 2018, Redox biology.

[2]  A. Bertolotti,et al.  Regulation of proteasome assembly and activity in health and disease , 2018, Nature Reviews Molecular Cell Biology.

[3]  R. Santos,et al.  Angiotensin-(1-7) reduces cardiac effects of thyroid hormone by GSK3Β/NFATc3 signaling pathway. , 2018, Clinical science.

[4]  A. Takano,et al.  AT1 receptor blockage impairs NF-κB activation mediated by thyroid hormone in cardiomyocytes , 2018, Pflügers Archiv - European Journal of Physiology.

[5]  A. Takano,et al.  S100A8/MYD88/NF-қB: a novel pathway involved in cardiomyocyte hypertrophy driven by thyroid hormone , 2017, Journal of Molecular Medicine.

[6]  L. C. Pomatto,et al.  Degradation of oxidized proteins by the proteasome: Distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways. , 2016, Molecular aspects of medicine.

[7]  E. J. Song,et al.  Proteasome inhibitors attenuated cholesterol-induced cardiac hypertrophy in H9c2 cells , 2016, BMB reports.

[8]  A. Gerdes,et al.  MuRF1 mono-ubiquitinates TRα to inhibit T3-induced cardiac hypertrophy in vivo. , 2016, Journal of molecular endocrinology.

[9]  B. Dahlmann.  Mammalian proteasome subtypes: Their diversity in structure and function. , 2016, Archives of biochemistry and biophysics.

[10]  P. Davis,et al.  Nongenomic actions of thyroid hormone , 2016, Nature Reviews Endocrinology.

[11]  Yiqiang Zhang,et al.  The mammalian target of rapamycin modulates the immunoproteasome system in the heart. , 2015, Journal of molecular and cellular cardiology.

[12]  P. Mohler,et al.  Role of Oxidative Stress in Thyroid Hormone-Induced Cardiomyocyte Hypertrophy and Associated Cardiac Dysfunction: An Undisclosed Story , 2015, Oxidative medicine and cellular longevity.

[13]  T. Fernandes,et al.  Increased Clearance of Reactive Aldehydes and Damaged Proteins in Hypertension-Induced Compensated Cardiac Hypertrophy: Impact of Exercise Training , 2015, Oxidative medicine and cellular longevity.

[14]  Hong-Xia Wang,et al.  Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP. , 2015, Journal of molecular and cellular cardiology.

[15]  J. Min,et al.  Muscle RING finger-1 attenuates IGF-I-dependent cardiomyocyte hypertrophy by inhibiting JNK signaling. , 2014, American journal of physiology. Endocrinology and metabolism.

[16]  S. Kaneko,et al.  Muscle-Specific RING Finger 1 Negatively Regulates Pathological Cardiac Hypertrophy Through Downregulation of Calcineurin A , 2014, Circulation. Heart failure.

[17]  F. Cacciapuoti.  Role of ubiquitin-proteasome system (UPS) in left ventricular hypertrophy (LVH). , 2014, American journal of cardiovascular disease.

[18]  D. A. Gomes,et al.  Angiotensin II Type 2 Receptor (AT2R) is Associated with Increased Tolerance of the Hyperthyroid Heart to Ischemia-Reperfusion , 2013, Cardiovascular Drugs and Therapy.

[19]  S. Day,et al.  The ubiquitin proteasome system in human cardiomyopathies and heart failure. , 2013, American journal of physiology. Heart and circulatory physiology.

[20]  Cam Patterson,et al.  Proteotoxicity and cardiac dysfunction--Alzheimer's disease of the heart? , 2013, The New England journal of medicine.

[21]  M. Eghbali,et al.  Pregnancy Is Associated with Decreased Cardiac Proteasome Activity and Oxidative Stress in Mice , 2012, PloS one.

[22]  Nobel C. Zong,et al.  Post-translational modification of cardiac proteasomes: functional delineation enabled by proteomics. , 2012, American journal of physiology. Heart and circulatory physiology.

[23]  Lan Huang,et al.  Regulation of the 26S Proteasome Complex During Oxidative Stress , 2010, Science Signaling.

[24]  J. Li,et al.  Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts. , 2010, Cardiovascular research.

[25]  P. Ping,et al.  Differential Regulation of Proteasome Function in Isoproterenol-Induced Cardiac Hypertrophy , 2010, Circulation research.

[26]  Noriaki Arakawa,et al.  Co‐ and post‐translational modifications of the 26S proteasome in yeast , 2010, Proteomics.

[27]  K. Ojamaa,et al.  Signaling mechanisms in thyroid hormone-induced cardiac hypertrophy. , 2010, Vascular pharmacology.

[28]  M. Carneiro-Ramos,et al.  Blockage of Angiotensin II type 2 receptor prevents thyroxine-mediated cardiac hypertrophy by blocking Akt activation , 2010, Basic Research in Cardiology.

[29]  C. Depré,et al.  Proteasome inhibitors and cardiac cell growth. , 2010, Cardiovascular research.

[30]  K. Lindsten,et al.  Stressing the ubiquitin-proteasome system. , 2010, Cardiovascular research.

[31]  S. Lecker,et al.  Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. , 2010, Cardiovascular research.

[32]  M. Carneiro-Ramos,et al.  Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK-3β/mTOR signaling pathway , 2009, Basic Research in Cardiology.

[33]  W. Dillmann.  Cardiac hypertrophy and thyroid hormone signaling , 2009, Heart Failure Reviews.

[34]  M. Willis,et al.  The ubiquitin-proteasome system in cardiac dysfunction. , 2008, Biochimica et biophysica acta.

[35]  M. Yacoub,et al.  Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. , 2008, Cardiovascular research.

[36]  Xuejun Wang,et al.  Protein quality control and degradation in cardiomyocytes. , 2008, Journal of molecular and cellular cardiology.

[37]  N. Maulik,et al.  Upregulation of myocardial 11S-activated proteasome in experimental hyperglycemia. , 2008, Journal of molecular and cellular cardiology.

[38]  G. Baumann,et al.  Suppression of Cardiomyocyte Hypertrophy by Inhibition of the Ubiquitin-Proteasome System , 2008, Hypertension.

[39]  B. Dahlmann.  Role of proteasomes in disease , 2007, BMC Biochemistry.

[40]  Á. Kenessey,et al.  Thyroid Hormone Stimulates Protein Synthesis in the Cardiomyocyte by Activating the Akt-mTOR and p70S6K Pathways* , 2006, Journal of Biological Chemistry.

[41]  M. Hori,et al.  Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. , 2006, Biochemical and biophysical research communications.

[42]  S. Powell.  The ubiquitin-proteasome system in cardiac physiology and pathology. , 2006, American journal of physiology. Heart and circulatory physiology.

[43]  P. Venditti,et al.  Thyroid hormone-induced oxidative stress , 2006, Cellular and Molecular Life Sciences CMLS.

[44]  R. Vabulas,et al.  Protein Synthesis upon Acute Nutrient Restriction Relies on Proteasome Function , 2005, Science.

[45]  C. Depré,et al.  Protein turnover in cardiac cell growth and survival. , 2005, Cardiovascular research.

[46]  G. Kahaly,et al.  Thyroid hormone action in the heart. , 2005, Endocrine reviews.

[47]  E. Liberti,et al.  Myocardial ultrastructure in cardiac hypertrophy induced by thyroid hormone—an acute study in rats , 2005, Virchows Archiv.

[48]  Holly McDonough,et al.  Muscle ring finger protein-1 inhibits PKCε activation and prevents cardiomyocyte hypertrophy , 2004, The Journal of cell biology.

[49]  Cam Patterson,et al.  Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Da-Zhi Wang,et al.  Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. , 2004, The Journal of clinical investigation.

[51]  Marco Sandri,et al.  Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.

[52]  A. Goldberg,et al.  Protein degradation and protection against misfolded or damaged proteins , 2003, Nature.

[53]  E. Liberti,et al.  Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[54]  Michael J Dunn,et al.  Hyperubiquitination of proteins in dilated cardiomyopathy , 2003, Proteomics.

[55]  F. B. Davis,et al.  Nongenomic actions of thyroid hormone on the heart. , 2002, Thyroid : official journal of the American Thyroid Association.

[56]  Michael R. Bristow,et al.  Regulation of Thyroid Hormone Receptor Isoforms in Physiological and Pathological Cardiac Hypertrophy , 2001, Circulation research.

[57]  K. Pelin,et al.  Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. , 2001, Journal of molecular biology.

[58]  K. Davies.  Degradation of oxidized proteins by the 20S proteasome. , 2001, Biochimie.

[59]  I. Klein,et al.  Thyroid hormone and the cardiovascular system. , 2001, Minerva endocrinologica.

[60]  J. Krieger,et al.  Stimulatory effect of dexamethasone on angiotensin-converting enzyme in neonatal rat cardiac myocytes. , 2000, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[61]  Jonathan W. Yewdell,et al.  Rapid degradation of a large fraction of newly synthesized proteins by proteasomes , 2000, Nature.

[62]  I. Klein,et al.  Thyroid hormone and the cardiovascular system. , 1990, The American journal of medicine.

[63]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[64]  Honglin Luo,et al.  Immune and non-immune functions of the immunoproteasome. , 2012, Frontiers in bioscience.

[65]  C. Patterson,et al.  The ubiquitin-proteasome system and cardiovascular disease. , 2012, Progress in molecular biology and translational science.

[66]  Q. Wang,et al.  Proteasome activation during cardiac hypertrophy by the chaperone H11 Kinase/Hsp22. , 2008, Cardiovascular research.